Genomics & Informatics

Korea Genome Organization (한국유전체학회)
권호 표지
DOI QR코드

DOI QR Code

Long non-coding RNA linc00152 acting as a promising oncogene in cancer progression

  • Seo, Danbi (Department of Science Education, Korea National University of Education) ;
  • Kim, Dain (Department of Science Education, Korea National University of Education) ;
  • Kim, Wanyeon (Department of Science Education, Korea National University of Education)
  • Received : 2019.09.23
  • Accepted : 2019.10.21
  • Published : 2019.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

The incidence and mortality rate of cancer continues to gradually increase, although considerable research effort has been directed at elucidating the molecular mechanisms underlying biomarkers responsible for tumorigenesis. Accumulated evidence indicates that the long non-coding RNAs (lncRNAs), which are transcribed but not translated into functional proteins, contribute to cancer development. Recently, linc00152 (an lncRNA) was identified as a potent oncogene in various cancer types, and shown to be involved in cancer cell proliferation, invasiveness, and motility by sponging tumor-suppressive microRNAs acting as a competing endogenous RNA, binding to gene promoters acting as a transcriptional regulator, and binding to functional proteins. In this review, we focus on the oncogenic role of linc00152 in tumorigenesis and provided an overview of recent clinical studies on the effects of linc00152 expression in human cancers.

Keywords

References

  1. Gschwind A, Fischer OM, Ullrich A. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer 2004;4:361-370. https://doi.org/10.1038/nrc1360
  2. Surget S, Khoury MP, Bourdon JC. Uncovering the role of p53 splice variants in human malignancy: a clinical perspective. Onco Targets Ther 2013;7:57-68.
  3. Nobili L, Ronchetti D, Taiana E, Neri A. Long non-coding RNAs in B-cell malignancies: a comprehensive overview. Oncotarget 2017;8:60605-60623. https://doi.org/10.18632/oncotarget.17303
  4. Do H, Kim W. Roles of oncogenic long non-coding RNAs in cancer development. Genomics Inform 2018;16:e18. https://doi.org/10.5808/GI.2018.16.4.e18
  5. Ransohoff JD, Wei Y, Khavari PA. The functions and unique features of long intergenic non-coding RNA. Nat Rev Mol Cell Biol 2018;19:143-157. https://doi.org/10.1038/nrm.2017.104
  6. Zhou L, Sun K, Zhao Y, Zhang S, Wang X, Li Y, et al. Linc-YY1 promotes myogenic differentiation and muscle regeneration through an interaction with the transcription factor YY1. Nat Commun 2015;6:10026. https://doi.org/10.1038/ncomms10026
  7. Paraskevopoulou MD, Hatzigeorgiou AG. Analyzing miRNA-lncRNA interactions. Methods Mol Biol 2016;1402:271-286. https://doi.org/10.1007/978-1-4939-3378-5_21
  8. Zhu J, Fu H, Wu Y, Zheng X. Function of lncRNAs and approaches to lncRNA-protein interactions. Sci China Life Sci 2013;56:876-885. https://doi.org/10.1007/s11427-013-4553-6
  9. Ma L, Cao J, Liu L, Du Q, Li Z, Zou D, et al. LncBook: a curated knowledgebase of human long non-coding RNAs. Nucleic Acids Res 2019;47:D128-D134. https://doi.org/10.1093/nar/gky960
  10. Chen X, Yan CC, Zhang X, You ZH. Long non-coding RNAs and complex diseases: from experimental results to computational models. Brief Bioinform 2017;18:558-576.
  11. Li Y, Zhao L, Zhao P, Liu Z. Long non-coding RNA LINC00641 suppresses non-small-cell lung cancer by sponging miR-424-5p to upregulate PLSCR4. Cancer Biomark 2019;26:79-91. https://doi.org/10.3233/CBM-190142
  12. Pang Q, Ge J, Shao Y, Sun W, Song H, Xia T, et al. Increased expression of long intergenic non-coding RNA LINC00152 in gastric cancer and its clinical significance. Tumour Biol 2014;35:5441-5447. https://doi.org/10.1007/s13277-014-1709-3
  13. Chen P, Fang X, Xia B, Zhao Y, Li Q, Wu X. Long noncoding RNA LINC00152 promotes cell proliferation through competitively binding endogenous miR-125b with MCL-1 by regulating mitochondrial apoptosis pathways in ovarian cancer. Cancer Med 2018;7:4530-4541. https://doi.org/10.1002/cam4.1547
  14. Huang Y, Luo H, Li F, Yang Y, Ou G, Ye X, et al. LINC00152 down-regulated miR-193a-3p to enhance MCL1 expression and promote gastric cancer cells proliferation. Biosci Rep 2018;38:BSR20171607. https://doi.org/10.1042/BSR20171607
  15. Wang H, Chen W, Yang P, Zhou J, Wang K, Tao Q. Knockdown of linc00152 inhibits the progression of gastric cancer by regulating microRNA-193b-3p/ETS1 axis. Cancer Biol Ther 2019;20:461-473. https://doi.org/10.1080/15384047.2018.1529124
  16. Bian Z, Zhang J, Li M, Feng Y, Yao S, Song M, et al. Long non-coding RNA LINC00152 promotes cell proliferation, metastasis, and confers 5-FU resistance in colorectal cancer by inhibiting miR-139-5p. Oncogenesis 2017;6:395. https://doi.org/10.1038/s41389-017-0008-4
  17. Zheng JJ, Du XJ, Wang HP, Zhou LY, Wang YJ, Zhang L, et al. Long non-coding RNA 00152 promotes cell proliferation in cervical cancer via regulating miR-216b-5p/HOXA1 axis. Eur Rev Med Pharmacol Sci 2019;23:3654-3663.
  18. Cai Q, Wang Z, Wang S, Weng M, Zhou D, Li C, et al. Long non-coding RNA LINC00152 promotes gallbladder cancer metastasis and epithelial-mesenchymal transition by regulating HIF-$1{\alpha}$ via miR-138. Open Biol 2017;7:160247. https://doi.org/10.1098/rsob.160247
  19. Sun K, Hu P, Xu F. LINC00152/miR-139-5p regulates gastric cancer cell aerobic glycolysis by targeting PRKAA1. Biomed Pharmacother 2018;97:1296-1302. https://doi.org/10.1016/j.biopha.2017.11.015
  20. Zheng L, Hu N, Zhou X. TCF3-activated LINC00152 exerts oncogenic role in osteosarcoma through regulating miR-1182/CDK14 axis. Pathol Res Pract 2019;215:373-380. https://doi.org/10.1016/j.prp.2018.12.031
  21. Ma P, Wang H, Sun J, Liu H, Zheng C, Zhou X, et al. LINC00152 promotes cell cycle progression in hepatocellular carcinoma via miR-193a/b-3p/CCND1 axis. Cell Cycle 2018;17:974-984. https://doi.org/10.1080/15384101.2018.1464834
  22. Zhang X, Tao W. Long noncoding RNA LINC00152 facilitates the leukemogenesis of acute myeloid leukemia by promoting CDK9 through miR-193a. DNA Cell Biol 2019;38:236-242. https://doi.org/10.1089/dna.2018.4482
  23. Cai J, Zhang J, Wu P, Yang W, Ye Q, Chen Q, et al. Blocking LINC00152 suppresses glioblastoma malignancy by impairing mesenchymal phenotype through the miR-612/AKT2/$NF-{\kappa}B$ pathway. J Neurooncol 2018;140:225-236. https://doi.org/10.1007/s11060-018-2951-0
  24. Liu D, Gao M, Wu K, Zhu D, Yang Y, Zhao S. LINC00152 facilitates tumorigenesis in esophageal squamous cell carcinoma via miR-153-3p/FYN axis. Biomed Pharmacother 2019;112:108654. https://doi.org/10.1016/j.biopha.2019.108654
  25. Ji J, Tang J, Deng L, Xie Y, Jiang R, Li G, et al. LINC00152 promotes proliferation in hepatocellular carcinoma by targeting EpCAM via the mTOR signaling pathway. Oncotarget 2015;6:42813-42824. https://doi.org/10.18632/oncotarget.5970
  26. Chen QN, Chen X, Chen ZY, Nie FQ, Wei CC, Ma HW, et al. Long intergenic non-coding RNA 00152 promotes lung adenocarcinoma proliferation via interacting with EZH2 and repressing IL24 expression. Mol Cancer 2017;16:17. https://doi.org/10.1186/s12943-017-0581-3
  27. Chen WM, Huang MD, Sun DP, Kong R, Xu TP, Xia R, et al. Long intergenic non-coding RNA 00152 promotes tumor cell cycle progression by binding to EZH2 and repressing p15 and p21 in gastric cancer. Oncotarget 2016;7:9773-9787. https://doi.org/10.18632/oncotarget.6949
  28. Xian-Li T, Hong L, Hong Z, Yuan L, Jun-Yong D, Peng X, et al. Higher expression of Linc00152 promotes bladder cancer proliferation and metastasis by activating the Wnt/${\beta}$-catenin signaling pathway. Med Sci Monit 2019;25:3221-3230. https://doi.org/10.12659/MSM.913944
  29. Wang X, Yu H, Sun W, Kong J, Zhang L, Tang J, et al. The long non-coding RNA CYTOR drives colorectal cancer progression by interacting with NCL and Sam68. Mol Cancer 2018;17:110. https://doi.org/10.1186/s12943-018-0860-7
  30. Zhang Y, Xiang C, Wang Y, Duan Y, Liu C, Jin Y, et al. lncRNA LINC00152 knockdown had effects to suppress biological activity of lung cancer via EGFR/PI3K/AKT pathway. Biomed Pharmacother 2017;94:644-651. https://doi.org/10.1016/j.biopha.2017.07.120
  31. Zhou J, Zhi X, Wang L, Wang W, Li Z, Tang J, et al. Linc00152 promotes proliferation in gastric cancer through the EGFR-dependent pathway. J Exp Clin Cancer Res 2015;34:135. https://doi.org/10.1186/s13046-015-0250-6
  32. Shen X, Zhong J, Yu P, Zhao Q, Huang T. YY1-regulated LINC00152 promotes triple negative breast cancer progression by affecting on stability of PTEN protein. Biochem Biophys Res Commun 2019;509:448-454. https://doi.org/10.1016/j.bbrc.2018.12.074
  33. Wu J, Shuang Z, Zhao J, Tang H, Liu P, Zhang L, et al. Linc00152 promotes tumorigenesis by regulating DNMTs in triple-negative breast cancer. Biomed Pharmacother 2018;97:1275-1281. https://doi.org/10.1016/j.biopha.2017.11.055
  34. Yu T, Xu Z, Zhang X, Men L, Nie H. Long intergenic non-protein coding RNA 152 promotes multiple myeloma progression by negatively regulating microRNA-497. Oncol Rep 2018;40:3763-3771.
  35. Zhang PP, Wang YQ, Weng WW, Nie W, Wu Y, Deng Y, et al. Linc00152 promotes cancer cell proliferation and invasion and predicts poor prognosis in lung adenocarcinoma. J Cancer 2017;8:2042-2050. https://doi.org/10.7150/jca.18852
  36. Yang Y, Sun X, Chi C, Liu Y, Lin C, Xie D, et al. Upregulation of long noncoding RNA LINC00152 promotes proliferation and metastasis of esophageal squamous cell carcinoma. Cancer Manag Res 2019;11:4643-4654. https://doi.org/10.2147/CMAR.S198905